[go: up one dir, main page]

NO20090314L - Faste doseformer av valsartan, amlodipin og hydroklorotiazid og fremgangsmate for a fremstille disse - Google Patents

Faste doseformer av valsartan, amlodipin og hydroklorotiazid og fremgangsmate for a fremstille disse

Info

Publication number
NO20090314L
NO20090314L NO20090314A NO20090314A NO20090314L NO 20090314 L NO20090314 L NO 20090314L NO 20090314 A NO20090314 A NO 20090314A NO 20090314 A NO20090314 A NO 20090314A NO 20090314 L NO20090314 L NO 20090314L
Authority
NO
Norway
Prior art keywords
valsartan
hydrochlorothiazide
amlodipine
dosage forms
preparing
Prior art date
Application number
NO20090314A
Other languages
English (en)
Inventor
Alan Edward Royce
Yatindra Joshi
Yu Cao
Ping Li
Madhusudhan Pudipeddi
Jiahao Zhu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38662673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090314(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20090314L publication Critical patent/NO20090314L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det beskrives faste mono-, bi- og trisjiktsdoseringsformer av en kombinasjon av valsartan, amlodipin og hydroklortiazid.
NO20090314A 2006-06-27 2009-01-20 Faste doseformer av valsartan, amlodipin og hydroklorotiazid og fremgangsmate for a fremstille disse NO20090314L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80588306P 2006-06-27 2006-06-27
PCT/US2007/072097 WO2008002905A2 (en) 2006-06-27 2007-06-26 Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same

Publications (1)

Publication Number Publication Date
NO20090314L true NO20090314L (no) 2009-01-26

Family

ID=38662673

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090314A NO20090314L (no) 2006-06-27 2009-01-20 Faste doseformer av valsartan, amlodipin og hydroklorotiazid og fremgangsmate for a fremstille disse

Country Status (22)

Country Link
US (2) US20100003321A1 (no)
EP (1) EP2037893A2 (no)
JP (1) JP2009542709A (no)
KR (1) KR20090021191A (no)
CN (2) CN103169711A (no)
AR (1) AR061627A1 (no)
AU (1) AU2007265138A1 (no)
BR (1) BRPI0713785A2 (no)
CA (1) CA2654986A1 (no)
CL (1) CL2007001870A1 (no)
EC (1) ECSP088987A (no)
IL (1) IL195797A0 (no)
MA (1) MA30529B1 (no)
MX (1) MX2008016532A (no)
NO (1) NO20090314L (no)
NZ (1) NZ573295A (no)
PE (2) PE20080991A1 (no)
RU (1) RU2449786C2 (no)
TN (1) TNSN08538A1 (no)
TW (1) TW200808379A (no)
WO (1) WO2008002905A2 (no)
ZA (1) ZA200810053B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3239B1 (ar) 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
WO2011001440A1 (en) * 2009-07-03 2011-01-06 Hetero Research Foundation Pharmaceutical compositions of valsartan
SI2486029T1 (sl) 2009-09-30 2015-10-30 Boehringer Ingelheim International Gmbh Postopki za pripravo z glukopiranozilom substituiranih benzil-benzenskih derivatov
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
CN102091069A (zh) * 2009-12-11 2011-06-15 浙江华海药业股份有限公司 缬沙坦和氨氯地平的复方制剂及其制备方法
CN101897675B (zh) * 2010-02-10 2012-11-21 温士顿医药股份有限公司 含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物
CN101829111B (zh) * 2010-05-23 2014-12-17 浙江华海药业股份有限公司 含有缬沙坦的固体制剂及其制备方法
CN102716132B (zh) * 2011-03-29 2015-09-30 石药集团中奇制药技术（石家庄）有限公司 复方氨氯地平/缬沙坦/氢氯噻嗪片及其制备方法
JP2015504878A (ja) * 2011-12-26 2015-02-16 ノバルティス アーゲー 錠剤及び有核剤
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102614190A (zh) * 2012-04-17 2012-08-01 北京哈三联科技股份有限公司 含有缬沙坦、氨氯地平和氢氯噻嗪的片剂及其制备方法
JP6018420B2 (ja) * 2012-06-05 2016-11-02 ニプロ株式会社 アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
MX358211B (es) 2012-07-23 2018-08-10 Landsteiner Scient S A De C V Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
CN103655580B (zh) * 2012-08-28 2017-12-01 海南中济医药科技有限公司 一种含有缬沙坦、苯磺酸氨氯地平和氢氯噻嗪的药物组合物及其制备方法
KR101931489B1 (ko) * 2012-10-12 2018-12-24 이에이 파마 가부시키가이샤 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제의 제조 방법
CN102846625A (zh) * 2012-10-18 2013-01-02 海口华仕联医药科技有限公司 一种稳定的缬沙坦、氨氯地平和氢氯噻嗪的药物组合及其制备方法
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN113181161A (zh) 2013-04-18 2021-07-30 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
CZ2013783A3 (cs) 2013-10-08 2015-04-15 Zentiva, K. S Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
CN105106962A (zh) * 2015-08-29 2015-12-02 西安力邦肇新生物科技有限公司 一种复方降压制剂及其应用
EP3463309B1 (en) * 2016-05-30 2020-06-17 Boehringer Ingelheim International GmbH Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine
MA46742A (fr) 2016-11-10 2019-09-18 Boehringer Ingelheim Int Composition pharmaceutique, méthodes de traitement et leurs utilisations
SG11201907435PA (en) 2017-02-27 2019-09-27 Idorsia Pharmaceuticals Ltd Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
US11382866B2 (en) * 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
ES3035734T3 (en) 2017-11-30 2025-09-08 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
WO2022132067A1 (en) * 2020-12-18 2022-06-23 Santa Farma Ilac Sanayii A.S. Stable bilayer tablet compositions
CN113171352A (zh) * 2021-04-15 2021-07-27 海南锦瑞制药有限公司 一种沙坦类降压复方制剂的制备方法
GR1010320B (el) * 2021-08-04 2022-10-11 Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057344A (en) * 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
RU2188636C2 (ru) * 1998-03-26 2002-09-10 Др. Редди'С Лабораторис Лтд. Стабильный фармацевтический препарат, содержащий амлодипина безилат и атенолол
AU2002226365A1 (en) * 2000-12-01 2002-06-11 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
AU2002242676B2 (en) * 2002-01-16 2008-05-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
KR100580168B1 (ko) 2003-03-21 2006-05-16 삼성전자주식회사 다중 홈 에이전트 제어장치 및 방법
US20050209288A1 (en) 2004-01-12 2005-09-22 Grogan Donna R Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use
US8158148B2 (en) 2004-05-21 2012-04-17 Accu-Break Technologies, Inc. Pharmaceutical tablets comprising two or more unitary segments
CN101052381A (zh) * 2004-11-05 2007-10-10 贝林格尔·英格海姆国际有限公司 包含替米沙坦和氨氯地平的双层片剂
CN100389830C (zh) * 2005-05-08 2008-05-28 广州市施柏医药科技有限公司 一种治疗高血压的药物组合物

Also Published As

Publication number Publication date
EP2037893A2 (en) 2009-03-25
MX2008016532A (es) 2009-01-19
RU2009102273A (ru) 2010-08-10
WO2008002905A2 (en) 2008-01-03
CN101478956A (zh) 2009-07-08
IL195797A0 (en) 2009-09-01
US8475839B2 (en) 2013-07-02
HK1133818A1 (en) 2010-04-09
ZA200810053B (en) 2009-11-25
CL2007001870A1 (es) 2008-06-13
MA30529B1 (fr) 2009-06-01
PE20080991A1 (es) 2008-09-05
NZ573295A (en) 2012-01-12
WO2008002905A3 (en) 2008-12-11
CN103169711A (zh) 2013-06-26
US20100003321A1 (en) 2010-01-07
PE20120542A1 (es) 2012-05-14
AU2007265138A1 (en) 2008-01-03
US20120164218A1 (en) 2012-06-28
JP2009542709A (ja) 2009-12-03
KR20090021191A (ko) 2009-02-27
TW200808379A (en) 2008-02-16
CA2654986A1 (en) 2008-01-03
TNSN08538A1 (en) 2010-04-14
CN101478956B (zh) 2013-03-20
AR061627A1 (es) 2008-09-10
ECSP088987A (es) 2009-01-30
RU2449786C2 (ru) 2012-05-10
BRPI0713785A2 (pt) 2012-10-30

Similar Documents

Publication Publication Date Title
NO20090314L (no) Faste doseformer av valsartan, amlodipin og hydroklorotiazid og fremgangsmate for a fremstille disse
NO20081310L (no) Faste doseringsformer for valsartan og amlodipin, og fremgangsmater for fremstilling av samme
NO20074436L (no) Stigerørsfri modulær undervanns brønnintervensjon, fremgangsmåte og anordning
DK1507529T3 (da) Kombination indeholdende valsartan, amlodipin og hydrochlorthiazid
DK1830855T3 (da) Faste, oralt indgivelige farmaceutiske indgivelsesformer indeholdende rivaroxaban med modificeret frigivelse
DK1711494T3 (da) Arylsubstituerede heterocykler, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
NL300703I2 (nl) Simeprevir, of een farmaceutisch aanvaardbaar zout daarvan, waaronder simeprevirnatrium.
NO20052559D0 (no) In-line syklonseparator.
NO20055369L (no) Borings-, perforerings- og formasjonsanalyse
EP1801484A4 (en) QUICK CONNECTOR
ATE457301T1 (de) Substituierte aryl-acylthioharnstoffe und verwandte verbindungen, virenreplikationshemmer
DK2051975T3 (da) Substituerede prolinamider, fremstilling deraf og anvendelse deraf som lægemiddel.
LTPA2017031I1 (lt) 8-[{1-(3,5-Bis-(trifluormetil) fenil) -etoksi}-metil]-8-fenil-1,7-diaza-spiro[4.5]dekan-2-ono hidrochlorido druska ir jos gamybos būdas
NO20070826L (no) Seddelhandteringssystem
DK1988090T3 (da) Imidazol-5-carboxylsyrederivater, fremgangsmåder til fremstilling af disse og anvendelse deraf
EP1961413A4 (en) FAST CRUMPING ORAL TABLET
NO20042767L (no) Sammenforingssystem, enkeltelementer og fremgangsmate for bruk av dette
NO20053856D0 (no) Bronn og skjot.
HK1128001A (en) Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
GB2439006A (en) Improved packer
NO20054587D0 (no) Bygning, grunnkonstruksjon for en bygning og fremgangsmate for fremstilling av slike
FR2901032B1 (fr) Obturateur rapide a double regime d'obturation.
SE0403128D0 (sv) A method for a processor, and a processor
LU91351B1 (de) Bio-magnum chew, tablette
TH98088A (no)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application